SMS Pharmaceuticals' Q2 FY 2025-26 Quarterly Results

Result Summary

• SMS Pharmaceuticals Ltd reported a 24.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 23.1%.
• Its expenses for the quarter were up by 21.8% QoQ and 17.5% YoY.
• The net profit increased 23.5% QoQ and increased 79.5% YoY.
• The earnings per share (EPS) of SMS Pharmaceuticals Ltd stood at 2.84 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

SMS Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, specializing in the production and development of active pharmaceutical ingredients (APIs) and intermediates. The company is known for its robust portfolio of products, which cater to a variety of therapeutic segments including anti-retrovirals, anti-depressants, anti-inflammatory, and anti-hypertensive medications. Based in India, SMS Pharmaceuticals Ltd has established a significant presence in both domestic and international markets, exporting its products to over 70 countries. The company continuously invests in research and development to expand its product offerings and improve manufacturing processes. However, specific recent developments or strategic initiatives are not detailed in the provided data.

Revenue

In the second quarter of the fiscal year 2026, SMS Pharmaceuticals Ltd reported a total income of ₹243.86 crores. This marks a quarter-over-quarter (QoQ) increase of 24.0% from ₹196.64 crores in Q1FY26. Additionally, there is a year-over-year (YoY) growth of 23.1% from ₹198.05 crores in Q2FY25. The significant increase in revenue demonstrates the company's ability to enhance its sales performance over both the last quarter and the same period in the previous year. The reasons behind this growth, however, are not detailed in the data provided.

Profitability

The profitability of SMS Pharmaceuticals Ltd has shown a marked improvement in Q2FY26. The company reported a profit before tax of ₹34.04 crores, which is a substantial QoQ increase of 39.7% from ₹24.37 crores in Q1FY26, and an impressive YoY rise of 74.2% from ₹19.54 crores in Q2FY25. After accounting for taxes amounting to ₹8.91 crores, the profit after tax stood at ₹25.31 crores, up 23.5% QoQ from ₹20.49 crores in the previous quarter and 79.5% YoY from ₹14.10 crores in Q2FY25. The earnings per share also increased to ₹2.84, reflecting a 22.9% QoQ growth from ₹2.31 and a 70.1% YoY growth from ₹1.67 in Q2FY25. These figures suggest strong underlying profitability, driven by an improvement in operational performance and possibly other factors not specified in the data.

Operating Metrics

During Q2FY26, SMS Pharmaceuticals Ltd reported total expenses of ₹209.82 crores. This represents a QoQ increase of 21.8% from ₹172.27 crores in Q1FY26 and a YoY increase of 17.5% from ₹178.51 crores in Q2FY25. Despite the rise in expenses, the company's ability to maintain a higher rate of income growth compared to expense growth indicates efficient cost management. The tax expense also increased significantly, with a QoQ rise of 57.7% and a YoY increase of 56.9%, which is consistent with the higher profit before tax. The data provided does not include specific operating metrics such as asset turnover or inventory turnover, nor does it specify any changes in operational strategy or efficiency measures that may have contributed to these financial outcomes.